NuPathe Files for IPO

NuPathe Inc., a Conshohocken, Penn.-based drug developer focused on the central nervous system, has filed for an $86.25 million IPO. It plans to trade on the Nasdaq under ticker symbol PATH, with Lazard Capital Markets and Leerink Swann serving as co-lead underwriters.

The company reports $11.3 million in 2009 revenue and a $15.6 million net loss.

NuPathe has raised $53 million in VC funding, from firms like Quaker BioVentures, Safeguard Scientifics, Battelle Ventures, Birchmere Ventures, S.R. One Ltd. www.nupathe.com

Leave a Reply

PE HUB Community

Join the 12522 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget